Literature DB >> 24841918

Emotional intelligence in association with quality of life in patients recently diagnosed with vestibular schwannoma.

Bibian M van Leeuwen1, Jacoba M Borst, Hein Putter, Jeroen C Jansen, Andel G L van der Mey, Adrian A Kaptein.   

Abstract

OBJECTIVE: The objective of this study was two-fold. First, to examine the levels of emotional intelligence in patients recently diagnosed with vestibular schwannoma, in comparison to those of healthy individuals and patients with other physical illness. Second, to evaluate the correlation between Emotional Intelligence and quality of life. STUDY
DESIGN: Cross sectional study in a university tertiary referral center.
METHODS: Consecutive patients (mean age [range], 56.4 [17-85] yr) diagnosed with vestibular schwannoma between April 2011 and October 2012 (N = 254). Sociodemographic characteristics, clinical characteristics, disease-specific quality of life (PANQOL), and Emotional Intelligence (TEIQue-SF) were assessed by questionnaire before the start of medical treatment.
RESULTS: Levels of Emotional Intelligence in patients with vestibular schwannoma (N = 178; response rate 70.1%) were significantly lower compared with healthy individuals and patients with cancer. Emotional Intelligence was highly positively correlated to disease-specific quality of life. Balance disorders and cranial nerve dysfunction made a significant negative contribution to the quality of life. For educational level, a significant positive contribution was found as well.
CONCLUSION: The substantial impact of a vestibular schwannoma-diagnosis on a psychological measure (i.e., Emotional Intelligence) in the affected patients as demonstrated in our study has important clinical and research implications when developing guidelines about counselling of these patients. This also has to be taken into account when making clinical decisions about the proposed treatment. Addressing Emotional Intelligence may be helpful in the development of a self-management program for patients with vestibular schwannoma.

Entities:  

Mesh:

Year:  2014        PMID: 24841918     DOI: 10.1097/MAO.0000000000000423

Source DB:  PubMed          Journal:  Otol Neurotol        ISSN: 1531-7129            Impact factor:   2.311


  6 in total

1.  Olfactory ensheathing cell tumor: A case report and review of the literature.

Authors:  Qingchun Mu; Haijun Gao; Pengfei Liu; Xitong Hu; X U Zheng; Peiwen Li; Ting Lei; Yuxue Sun; Gang Zhao; Haiyan Huang; Xinyu Hong
Journal:  Oncol Lett       Date:  2015-03-16       Impact factor: 2.967

2.  Validation of the facial dysfunction domain of the Penn Acoustic Neuroma Quality-of-Life (PANQOL) Scale.

Authors:  Wouter L Lodder; Guleed H Adan; Chung S Chean; Tristram H Lesser; Samuel C Leong
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-04-08       Impact factor: 2.503

3.  Conservative treatment of vestibular schwannoma: growth and Penn Acoustic Neuroma Quality of Life scale in French language.

Authors:  P A Oddon; M Montava; F Salburgo; M Collin; C Vercasson; J P Lavieille
Journal:  Acta Otorhinolaryngol Ital       Date:  2017-08       Impact factor: 2.124

4.  Emotional Intelligence as A Predictor of Health-Related Quality of Life in Breast Cancer Survivors.

Authors:  Sahar Mirzaei; Ahmad Izadi Tame; Robab Anbiaie; Fateme Moradipour; Malihe Nasiri; Camelia Rohani
Journal:  Asia Pac J Oncol Nurs       Date:  2019 Jul-Sep

5.  What determines quality of life in patients with vestibular schwannoma?

Authors:  Ineke M J Pruijn; Wietske Kievit; Mayke A Hentschel; Jef J S Mulder; Henricus P M Kunst
Journal:  Clin Otolaryngol       Date:  2020-12-28       Impact factor: 2.597

6.  Current Recommendations for Patient-Reported Outcome Measures Assessing Domains of Quality of Life in Neurofibromatosis Clinical Trials.

Authors:  Pamela L Wolters; Ana-Maria Vranceanu; Heather L Thompson; Staci Martin; Vanessa L Merker; Andrea Baldwin; Carolina Barnett; Kimberley S Koetsier; Cynthia M Hingtgen; Christopher J Funes; James H Tonsgard; Elizabeth K Schorry; Taryn Allen; Taylor Smith; Barbara Franklin; Stephanie Reeve
Journal:  Neurology       Date:  2021-07-06       Impact factor: 11.800

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.